JUL 2 8 7005 SE

FORM PTO-1449	9							COMMERCE	ATTY. DOCKET NO).:	SERIAL NO.:		
(REV. 7-80)								MARK OFFICE	200.1134CON		10/827,623		
	LIST	OF PRIC	OR ART	CITED	BY A	PPLIC	CANT		APPLICANT(S): Benjamin OSHLACH	Cet al.			
	(Use s	several shee	ets if neces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
							U.S	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOCUM	ENT NUM	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	ВА												
	BB												
	ВС												
-	BD						<u> </u>						
	BE										<u></u>		
							FORE	IGN PATENT D	OCUMENTS			•	
		DOCUM	ENT NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
												YES	NO
	BF												
	BG												
	ВН												
	ВІ												
	ВЈ												
				0	THER F	PRIOR /	ART (Inc	cluding Author, T	itle, Date, Pertinent Pa	ges, Etc.)			
	ВК												
	BL												
	BN									_			
	во												
	BP BP												
	BQ		·										
	BR	Miakows 274.	ski et al., "l	nhibition	n of Spir	nal Opio	oid Anal	gesia by Supras	pinal Administration of	Selective Opioid A	Antagonists", Brain F	Research (1992)	, 30:263-
EXAMINER		•							DATE CONSIDERE	D			
*EXAMINER: Init	tial if refere	ence conside	ered, whet	her or no	ot citatio	on is in	conform	ance with MPEF	609; Draw line throug	h citation if not in	conformance and no	ot considered. Ir	nclude

FORM PTO-1449 (REV. 7-80)	-			 (J.S. DEF PATENT	PARTMI F AND T	ENT OF (COMMERCE ARK OFFICE	ATTY. DOCKET NO 200.1134CON).:	SERIAL NO.: 10/827,623		
	LIST	OF PR	IOR AR	T CITED	BY A	PPLIC	CANT		APPLICANT(S): Benjamin OSHLACI	Cet al.			
	(Use s	everal sh	eets if ne	cessary)					FILING DATE: December 29, 2003		GROUP: 1614		
							U.S.	PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOCU	JMENT N	UMBER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	DA												
	DB										}		
	DC												
	DD												
	DE												
	DF												
	DG												
							FOREIG	GN PATENT D	OCUMENTS				
		DOCL	JMENT N	UMBER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
												YES	NO
	DH					-							
	DI												
	DJ												
	DK												
	DL												
	I,			0	THER F	PRIOR A	ART (Inclu	ıdina Author. T	itle, Date, Pertinent Pa	ges, Etc.)	<u> </u>		
	DM	Alavre Pham	ez-Fuente n Pharmo		fectiven	ess of F			of a New Ora Naltrexo		ease System in Mo	phine Analgesia	"; J.
	DN	Alvare	ez-Fuente	s, et al., "P	reclinica	al Study	of an Ora	al Controlled R	elease Naltrexone Con	nplex in Mice"; J. P	harm Pharmacol (2	000), 52:659-66	3.
	DO								velopment of Naltrexon				
	DP	Baum	et al., "Ti	ne Impact o	of the Ad	ddition o	of Naloxor	ne on thr Use a	nd Abuse of Pentazoci	ne"; Public Health	Reports (1987) Vol	. 102, No. 4 p. 4	26-429.
	DQ	Rapal	ka et al., "	Discovery	of Nove	l Opioid	Medication	ons"; NIDA Re	search Monograph 147	′ (1995) p. 55-83.			
	DR	Bloom 1349.	n et al., "C	linical Stud	lies with	n Naloxo	one/Metha	adone in a Rati	o of 1:20"; 5 th National	Conference on Me	ethadone Treatmen	t (1973) Vol 2, p.	1342-
EXAMINER	•			,					DATE CONSIDERE	D		-	
*EXAMINER: Initiation of this form to	al if refere with next o	nce cons	idered, w	hether or n	ot citation	on is in o	conforma	nce with MPEF	609; Draw line throug	h citation if not in o	conformance and no	ot considered. In	nclude

FORM PTO-1449									COMMERCE	ATTY, DOCKET N	0.:	SERIAL NO.:		
(REV. 7-80)									MARK OFFICE	200.1134CON		10/827,623	 	
		OF PF				ВҮ А	PPLIC	CANT		APPLICANT(S): Benjamin OSHLAC	K et al.	т		
	(Use s	several s	heets if	necess	sary)					FILING DATE: December 29, 200	3	GROUP: 1614		
								U.S	S. PATENT DOC					
*EXAMINER INITIAL		DOC	UMENT	NUME	BER				DATE	NAME	CLASS	SUBCLASS	FILING DA	
	EA													
	EB		·											
	EC													
	ED													
	EE													
	EF													
	EG									· · · · · · · · ·				
	1 20		LL		<u> </u>	<u></u>		FORE	EIGN PATENT D	OCUMENTS				
		DOC	UMENT	NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
			ONLIN	1101111	DEIX								YES	NO
	ļ <u> </u>					<u> </u>	Т	I					 	
	EH				ļ			ļ						
	EI				ļ	1								
	EJ	ļ												
	EK				_		ļ							
	EL					<u> </u>						L	<u> </u>	
		,		_	0	THER F	RIOR A	ART (Inc	cluding Author, T	itle, Date, Pertinent P	ages, Etc.)			
	EM	Brisc	oe et al.	., "Metl	hoclocir	namox	: Time (Course	of Changes in A	fetnanil-Reinforced Ri	hesus Monkeys"; Ps	sychopharmacolog	y (2000) 148:3	93-399.
	EN	Abst	act of B	romm,	, et al., '	'A Sens	sitive Me	ethod to	Evaluate Effect	s of Analgesics in Mar	"; Meth and Find E	optl Clin Pharmaco	l 5 (8) (1983) p	o. 545-551.
	EO	Bullir	ngham e	et al., "(Clinical	Pharan	ncokine	tics of N	larcotic Agonist-	Antagonist Drugs"; Cli	nical Pharm (1983)	8: 332-343.		
	EP		nlim, et a 56-564.	al. "Eff	ect of N	laloxon	e on the	Analge	esic Activity of M	ethadone in a 1:10 Or	al Combination"; Cli	n Pharmacol and 1	There (1974) V	ol. 15; No. 6
	EQ	Caru	so et al.	, "Meth	hadone	and Na	loxone	in Com	bination (Naldon	e®) for the Treatment	if Heroin Addicts"; E	Bristol Laboratories	, pp.1336-134	1F
_	ER	Cher	ny, Nath	nan I., '	"Opioid	Analge	sics"; D	rugs (1	996) May:51 (5)	рр. 713-737.				
	ES	Chia	ng, et al	l. "Clini	ical Eva	luation	of a Na	Itrexone	Sustained-Rele	ase Preparation"; Dru	g and Alcohol Depe	ndence (1985) 16,	pp.1-8.	
EXAMINER										DATE CONSIDER	ED			
*EXAMINER: Initi						ot citation	on is in	conform	nance with MPEF	P 609; Draw line throu	gh citation if not in c	onformance and n	ot considered.	Include

FORM PTO-1449 (REV. 7-80)	· · · · · ·								COMMERCE MARK OFFICE	ATTY. DOCKET NO 200.1134CON	.:	SERIAL NO.: 10/827,623		
	LIS	T OF PR	IOR A	ART C	CITED	BY A	PPLIC	ANT		APPLICANT(S): Benjamin OSHLACK	et al.			
	(Use	several sh	eets if	necess	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U.S	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOCUM	/ENT N	NUMBE	≣R				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	FA													
	FB			1.5										
	FC													-
	FD													
	FE													
	FF													
	FG													
								FORE	IGN PATENT D	OCUMENTS				
		DOCU	MENT N	NUMBE	ER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	NC
													YES	NO
	FH													
	FI													
	FJ													
	FK													
					0	THER P	RIOR A	ART (Inc	cluding Author, T	itle, Date, Pertinent Pag	ges, Etc.)			
	FL	Chiang	et al., "	'Kinetic	cs of a l	Naltrexo	ne Sus	tained-F	Release Prepara	tion"; Clin Pharmacol T	hera (1984) Vol 3	6 No. 5, pp.704-708	l	
	FM	Comer	et al., "	Depot	Naltrex	one: Lo	ng-lasti	ng Anta	gonism of the E	fects Of Heroin un Hun	nans"; Psychopha	rmacology (2002) 1	59, pp.351-360.	
	FN	Crabtre	e et al.	, "Revi	iew of N	laltrexo	ne, a lo	ng-actin	g Opiate Antago	nist"; Clinical Pharmacy	/, Vol. 3 (1984) p	o.273-280.		
	FO	Crain e liability"	t al., "A ; Dept.	ntagor of Ne	nists of uroscie	Excitato	ry Opio ert Eins	id Rece	eptor Functions E llege of Medicine	nhance Morphine's An Pain 82 (1999)pp.1-11	algesic Potency a	and Attenuate Opioio	Tolerance/depo	endence
	FP	Crain e liability	t al., "A '; Dept.	ntagor of Ne	nists of uroscie	Excitato	ry Opio ert Eins	oid Rece stein Co	eptor Functions E llege of Medicine	Enhance Morphine's An e Pain 84 (2000) pp.121	algesic Potency a -131.	and Attenuate Opioio	Tolerance/depe	endence
	FQ	Fink et	al., "na	loxone	in Her	oin Dep	endenc	e"; Clin	Pharm and The	a. Vol 9, No. 5;pp.568-	577.			
	FR	Fishma	n et al.	, "Disp	osition	of Nalo	cone-7,	8-3H in N	Normal & Narcot	ic Dependent Men"; J. I	Pharm. And Expe	r. Thera (1973)Vol 1	0 No. 2;pp.575-	580.
EXAMINER		,								DATE CONSIDERE	D			
*EXAMINER: Initi						ot citatio	n is in o	conform	ance with MPEF	609; Draw line through	n citation if not in	conformance and no	ot considered. In	nclude

FORM PTO-1449 (REV. 7-80)			<u> </u>					COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/827,623		
	LIST	OF PRIOR	R ART	CITED	BY A	PPLIC	ANT		APPLICANT(S): Benjamin OSHLACK et	t al.			
	(Use s	everal sheets	s if neces	ssary)					FILING DATE: December 29, 2003		GROUP: 1614		
							U.S	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOCUME	NT NUM	1BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	GA												
	GB												
	GC												
	GD												
	GE												
	GF												
	GG GG									1		_	
	1_00	LL			L	٠	FORE	IGN PATENT C	OCUMENTS	<u> </u>	L	_	.,
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION													
		DOCOME		IDEIX				5/112	Cookiiki	02.00	00502.00	YES	NO
	ļ			1		1							
	GH					<u> </u>				<u> </u>			<u> </u>
		T		0	THER F	RIOR A	ART (Inc	cluding Author, T	itle, Date, Pertinent Pages	s, Etc.)			
	GI	Fraser, Al 386.	bert D.,	et al., "C	inical T	oxicolog	gy of Dn	ugs Used in the	Treatment of Opiate Depe	endency"; Clinio	al Toxicology I (199	0) Vol 10, No. 2	; pp.375-
	GJ	Freye et a	al., "Effec	ts of Tra	madol	and Tilio	dine/Nal	oxone on Oral-C	aecal Transit & Pupillary I	light Reflex'; Ar	zneim-Forsch/Drug	Res. 50(I)(2000)pp. 24-30.
	GK	Fudala, et	t al., "Effe	ects of B	upreno	rphine a	snd Na	loxone in Morph	ine-Stabilized Opioid Addi	cts"; Drug and	Alcohol Dependence	e 50 (1998) pp.	1-8.
	GL	Fudala et	al., "Hur	nan Pha	rmacolo	ogy and	Abuse I	Potential Of Nali	mefene"; Clin Pharm and	Thera (1991) V	ol 49, 3, pp. 300-306	6.	
	GM								ene"; Clin Pharm and The				
	GN	1							reatment of Heroin Addict			nt (1995) Vol 12	, 1, pp. 35-
	GO	Ghodse, e	et al., "O	pioid ana	algesics	and Na	arcotic A	ntagonists"; Sid	e Effects of Drugs (2000)	Annual 23, chp	t 8 pp. 96-113.		
EXAMINER							·-	-	DATE CONSIDERED				
*EXAMINER: Initi					ot citatio	on is in o	conform	ance with MPEF	P 609; Draw line through c	itation if not in	conformance and no	t considered. Ir	nclude

FORM PTO-14 (REV. 7-80)	49							MMERCE RK OFFICE	ATTY. DOCKET 200.1134CON	NO.:	SERIAL NO.: 10/827,623		
	LIST O	F PRIC	R ART	CITED	BY AF	PPLIC	ANT		APPLICANT(S): Benjamin OSHLA	CK et al.			
	(Us	e severa	l sheets	if necessa	ary)				FILING DATE: December 29, 200	03	GROUP: 1614		
							U.S. PA	ATENT DOC	UMENTS				
*EXAMINER INITIAL		DOC	JMENT	NUMBE	ER		1	DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	НА						 						
	НВ			_									
	нс			_			<u> </u>	-					
	НD												
	не				_								
	HF			_	<u> </u>								
	HG	<u> </u>			<u></u>								
						F	FOREIGN	PATENT D	OCUMENTS		1		
		DOC	UMENT	NUMBE	ER		1	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
												YES	NO
	нн										<u> </u>		<u> </u>
		· · · · · · · · · · · · · · · · · · ·		OTHE	R PRI	OR AR	RT (Includ	ing Author,	Title, Date, Pertinent	Pages, Etc.)	 		
	ні			n, M.D. F. pp. 193-1		A New	v Method	for Detoxifyi	ng Opoiod-Depende	nt Patients"; J.	Substance Abuse	Treatment (19	999)
<u>. </u>	НЈ	Gold,	et al. "R	Rapid Opi	oid De	toxifica	ation Dur	ing General A	Anesthesia"; Anesthe	siology (1999)	Vol 91, No 6, pp	. 1639-1647.	
	нк			al., "Cor 7, No 3,				macology of	Short-Acting µu Op	ioids in Drug A	busers"; J. Pharm	and Exper Th	пега
	HL	Gupta	ı, et al., '	"Morphin	e Com	bined v	with Doxa	apram or Nal	oxone"; Anesthesia (1974) Vol 29,	рр. 33-39.		
	НМ			"Clinical I)(1985)p				evelopment o	of Dependence durin	g Oral Therapy	with Tramadol";	Arzniem-Fors	ch/Drug
	HN		n et al., " 73-176.	The effec	t of La	motrigi	gine on Na	iloxone-preci	pitated Opiate withd	rawal"; Drug a	nd Alcohol Deper	idence (1998)	Vol 52,
	но		n et al., " op. 251-2		tudy of	Dextro	omethorp	han in Nalox	one-Precipitated Op	iate Withdrawa	l"; European J. of	Pharm. (1996	o) Vol
EXAMINER									DATE CONSIDE	RED			
*EXAMINER: considered. Inc	Initial if a	reference	e conside	ered, whe	ther or	not cita	ation is in	n conformanc	te with MPEP 609; D	Oraw line throu	gh citation if not i	n conformanc	e and not

LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) LIST OF PRIOR ART CITED BY APPLICANT US. PATENT DOCUMENTS US. PATENT DOCUMENTS US. PATENT DOCUMENTS LIA LIA LIA LIA LIA LIA LIA LI	FORM PTO-14	49						COMMERCE	ATTY. DOCKET	`NO.:	SERIAL NO.:		· <u></u>
Benjamin OSHLACK et al.	(REV. 7-80)							IARK OFFICE			10/827,623		
#EXAMINER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE FAPROPRIATE #EXAMINER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE FAPROPRIATE ##EXAMINER DATE D							CANT			ACK et al.			
*EXAMINER DOCUMENT NUMBER DATE NAME CLASS SUBCLASS FILING DATE IF APPROPRIATE ID IC ID ID IF IG FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Esc.) III Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Conset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 102-174. IL Stevens et al., "Nonset, Excisitory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1991) Vol 75, pp. 210-211. IM Since et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Ackholo Labuse (1994) Vol 26, ap. 445-455. BN Strine et al., "Toge of Drug Combinations in Treatment of Opiopd Withdrawal", J. Clinical Psych. (1992) Vol 12, No. 3, pp. 203-209. IO Stoller et al., "Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No. 3, pp. 898-993. IR Strain et al., "Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No. 3, pp. 898-993. IR Strain et al., "Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No. 3, pp. 898-993. IS Tai, et al., "Nalirexone: An Antagonist Therapy for Heroin Addiction", NIDA (1997) 5 pages DATE CONSIDERED		(U	se several she	ets if no	ecessary)					03	1	··	
INTIAL IA IB IC ID ID IE IF FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO OTHER PEIOR ART (including Author, Title, Date, Pertinent Pages, Etc.) IH OTHER PEIOR ART (including Author, Title, Date, Pertinent Pages, Etc.) IS Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1990) Vol 27s, p. p. 813-846. IK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1991) Vol 17s, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1981) Vol 17s, pp. 210-221. IM Stinc et al., "Reflects of Opiate Withdrawal-like Symptons by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 444-548. IN Stinc et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 983-993. IQ Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-644. IS Tal, et al., "Nalfrexone: An Antagonist Therapy for Heroin Addiction", NIDA (1997) 5 pages DATE CONSIDERED							U.S	. PATENT DOC	CUMENTS				
IB IC ID ID IE IF IG FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO IH OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) U Schuh et al., "Buperenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Sonset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions"; Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 226, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal", J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers", J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. JQ Strain et al., "Except Thera (1992) Vol 261, No 3, pp. 985-993. IR Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers", Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tal, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction", NIDA (1997) 5 pages DATE CONSIDERED			DOCUME	ENT NU	JMBER			DATE	NAME	CLASS	SUBCLASS	I .	
III Schuh et al., "Boduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Psychopharmacology (1994) Vol 20, 4, pp. 445-438. IN Since et al., "Effects of Buprenorphine, horphine to Project Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 218, no 3, pp. 985-993. IN Since et al., "Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 218, no 3, pp. 985-993. IQ Strain et al., "Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 218, No 3, pp. 985-993. IR Strain et al., "Effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 218, No 3, pp. 985-993. IR Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2001) Vol 154, pp. 230-242. IR Strain et al., "Effects of buprenorphine versus buprenorphine and naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2001) Vol 154, pp. 230-242. IR Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Perceipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 261, No 3, pp. 645-646. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages EXAMINER		IA											
ID IE IF IG DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO IH OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans", J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Osnest, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans", Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Escitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions': Psychopharmacology (1991) Vol 75, pp. 210-2211. IM Since et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stince et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stince et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stince et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stince et al., "Refects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Perceipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 261, No 3, pp. 985-993. DATE CONSIDERED		ΙΒ											
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO IH OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Reflects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. Province of Province And Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages EXAMINER DATE CONSIDERED		IC											
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO IH OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, p. 836-846. IK Schuh et al., "Superior and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1981) Vol 175, pp. 210-211. IM Stine et al., "Rolation of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of Buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Caute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers", Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. DATE CONSIDERED		ID											
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO IH OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) JI Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) vol 278, 2, pp. 836-846. IK Schuh et al., "Sonset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1981) vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages DATE CONSIDERED		IE											
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO IH OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions': Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine/naloxone in nojoid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages DATE CONSIDERED		IF											
DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO IH OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. 10 Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Actue Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. DATE CONSIDERED		IG											
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) J Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. JK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. JK Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1981) Vol 75, pp. 210-211. JK Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. JN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. JK Stoller et al., "Effects of Buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. JP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. JK Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. JK Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. JK Strain et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages DATE CONSIDERED		•				•	FORE	GN PATENT D	OCUMENTS				
III OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) IJ Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages DATE CONSIDERED			DOCUME	ENT NU	JMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) J Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages												YES	NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) J Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions": Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages		IH											
IJ Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) Vol 278, 2, pp. 836-846. IK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions': Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages DATE CONSIDERED		<u> </u>	- 1		OTHER I	PRIOR A	RT (Inc	luding Author,	Title, Date, Pertinen	t Pages, Etc.)			
IK Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) Vol 145, pp. 162-174. IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions': Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages DATE CONSIDERED		IJ		al., "Buj	prenorph	ine, Mor	phine ar	nd Naloxone Eff			aintenance in Hui	nans"; J. Phar	m and
IL Stevens et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions': Psychopharmacology (1981) Vol 75, pp. 210-211. IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. 10 Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages EXAMINER DATE CONSIDERED		IK	Schuh et a	ıl., "On	set, Magi	nitude ar	nd Durat	ion of Opioid B	lockade Produced by	/ Buprenorphin	e and Naltrexone	n Humans";	
IM Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) Vol 20, 4, pp. 445-458. IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages EXAMINER DATE CONSIDERED		IL	Stevens et	al., "N	onspecifi	c Excita	tory Effe	ects of Morphine	e: Reverse-Order Pre	ecipitated Withou	lrawal and Dose-I	Oose Interaction	ns':
IN Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) Vol 12, No 3, pp. 203-209. IO Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages EXAMINER DATE CONSIDERED		IM	Stine et al	., "Redı	uction of	Opiate V	Withdray	wal-like Sympto		se during Metha	done and Bupren	orphine Maint	enance";
IO Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) Vol 154, pp. 230-242. IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages DATE CONSIDERED		, ni								I Clinical Pevo	h (1002) Vol 12	No 3 nn 203	-209
IP Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) Vol 261, No 3, pp. 985-993. IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages DATE CONSIDERED												•	
IQ Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) Vol 148, pp. 374-383. IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages EXAMINER DATE CONSIDERED			Strain et a	ıl., "Acı	ite Effect	s of Bup	renorph	ine, hydromorpl					
IR Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) Vol 267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages EXAMINER DATE CONSIDERED		IQ	Strain et a	ıl., "Effe	ects of bu	prenorp			ne/naloxone tablets	in non-depende	nt opioid abusers'	'; Psychopharr	nacology
267, No 2, pp. 624-634. IS Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages EXAMINER DATE CONSIDERED		-	1										
EXAMINER DATE CONSIDERED		IR				Withdra	wal by F	Pentazocine in M	lethadone-Maintain	ed Volunteers";	J. Pharm and Exp	per Thera (199	3) Vol
		IS	Tai, et al.,	, "Naltro	exone: A	n Antago	onist The	erapy for Heroin	Addiction"; NIDA	(1997) 5 pages			
#EVAMINED. Initial if reference considered, whether or not citation is in conformance with MDED 600. Draw line through citation if not in conformance and no	EXAMINER								DATE CONSIDI	ERED			
considered. Include copy of this form with next communication to applicant.									ce with MPEP 609; 1	Draw line throu	gh citation if not i	n conformanc	e and not

FORM PTO-144 (REV. 7-80)	19								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	VO.:	SERIAL NO.: 10/827,623			
	LIST O	F PRI	OR AI	RT CI	TED E	BY AP	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	CK et al.				
	(Us	e sever	al shee	ets if ne	ecessar	y) 				FILING DATE: December 29, 2003		GROUP: 1614			
								U.S.	PATENT DOC	UMENTS					
*EXAMINER INITIAL		DOC	CUME	NT NL	JMBEI	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP		
	JA														
	JB														
	JC														
	JD												_		
	JE													·	
	JF														
JG JG															
	FOREIGN PATENT DOCUMENTS														
	JH														
					ОТНЕ	R PRIC	R AR	T (Incl	uding Author,	Γitle, Date, Pertinent F	ages, Etc.)				
	JI	Umt 181-		et al., "	Naltre	xone sl	hortene	ed opio	id detoxificatio	n with buprenorphine	"; Drug and A	alcohol Dependen	ce (1999) Vol	56 pp.	
	JK	Vac	carino	et al., '	"Enoge	nous (Opiates	s: 1999	"; Peptides 21 ((2000) pp. 1975-2034					
-	JL	Wan	ıg et al	., "Inve	erse Ag	gonists	and no	eutral a		opioid receptor (MOI		le of basal recepto	or signaling in	narcotic	
	JM	Way	et al.,	"Resp	onsivit	ty to N	aloxon	ie durir	ng Morphine De	ependence"; Annals N	ew York Aca	demy of Sciences,	pp. 252-261.		
	JN	Wei	nberg e	et al., "	Sublin	gual a	bsorpti	ion of s	selected opioid	analgesics"; Clin Phar	m Thera (198	8) Vol 44, No 3, j	р. 335-342.		
	JO	Lim	ls, et al ited Ar	ntinoci	vivo Pł ceptive	narmac Toler	ologic ance a	al Chai	racterization of enuates Morphi	SoRI 9409, a Nonpep one Physical Depende	tidic Opioid μ nce"; J. Pharr	a-Agonist/ô-Antag n and Exper Thera	gonist that Prod a (2001) Vol 2	duces 97, No 2,	
	JР	Woo	lak, Al	ex, "D	rug Tre	eatmen	it for C)pioid I	Dependence"; A	Australian Prescriber (2001) Vol 24	No 1, pp. 4-6.			
	JQ	Wri	ght et a	ıl., "Ac	ute ph	ysical	depend	dence i		eated naloxone-precip			dose of metha	done";	
	JR	Zhu	et al.,	"Naltro	exone-	precipi	itated r	norphi	ne withdrawal i	n infant rat is attenuat) Vol 150, pp. 325-33	ed by acute a	dministration if N	OS inhibitors	but not	
EXAMINER		-		-	<u> </u>	<u>-</u>				DATE CONSIDER					
*EXAMINER:	Initial if	referen		sidered						e with MPEP 609; Dr	aw line throu	gh citation if not i	n conformance	e and not	

FORM PTO-144 (REV. 7-80)	19		-				OF COMMER DEMARK OFFI		ATTY. DOCKET 200.1134CON	`NO.:	SERIAL NO.: 10/827,623		
	LIST O	F PRIOR	R ART C	ITED B	SY API	PLICA	NT		APPLICANT(S): Benjamin OSHLA	ACK et al.			
	(Us	e several s	sheets if 1	necessar	y)				FILING DATE: December 29, 20	03	GROUP: 1614		
							U.S. PATENT	DOC	CUMENTS				,
*EXAMINER INITIAL		DOCU	MENT N	UMBEF	2		DATE	·	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	KA												
	КВ												
	KC												
	KD												
	KE			<u> </u>									_
	KF												
	KG												
						FC	REIGN PATE	NT D	OCUMENTS				
		DOCUI	MENT N	UMBER	₹		DATE		COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
				_								YES	NO
	КН												
				OTHER	R PRIO	R ART	(Including Aut	hor,	Title, Date, Pertinen	t Pages, Etc.)			
	KI	Han et	al., "Muc and muc	coadhes	ive bud e perfo	ccal dis	ks for novel nal	lbuph 1 J. Pl	nine prodrug controll harm (1999) Vol 17	ed delivery; effo 7, pp. 201-209.	ect of formulation	variable on di	rug
	KJ								(1983) Vol 12:7, pp				
	KK	Harris e	et al., "Bı	uprenorp	hine ar	nd Nalo		istrat	ion in opiate depend		bilized on subling	ual buprenorp	hine";
	KL	Hawke:		Effect of	enterio	c-releas			oxone on intestinal t	ransit in volunt	eers taking codeir	e"; Aliment P	harm
	KM	Högger	et al., "C	Comparis	son of t	ilidine/	naloxone, trama	adol a	and bromfenac in ex harm and Thera (19	perimental pain	: a double-blind r	andomized cro	ossover
	1/21						_		ere's Clinical Anesth			993-1011	
	KN KO								rely antagonize excit				hereby
		increas	ing its an	tinocice	ptive p	otency	and attenuating	toler	rance/dependence			,	
	КР	Howes	et al., "T	he Pharr	nacolo	gy of T	R5109, a new N	Varco	tic Agonist/Antagor	ist Analgesic";	NIDA Research (1979) pp. 99-	105.
	КQ		g et al., "I p 649-65		on and	metabe	oliam of codorp	hone	in the rat, dog, and	man"; Drug Me	etabolism and Dis	position (1982	?) Vol 10,
EXAMINER		•							DATE CONSIDI	ERED			
*EXAMINER: considered. Inc								mano	ce with MPEP 609;	Draw line throu	gh citation if not	n conformanc	e and not

FORM PTO-14 (REV. 7-80)	LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) APPLICANT(S): Benjamin OSHLACK et al.													
	LIST C	OF PRI	IOR A	RT C	ITED :	BY AF	PPLIC	ANT						
	(Us	se seve	ral shee	ets if n	ecessa	ry)					03			
				-				U.S.	PATENT DOC	UMENTS			_	
*EXAMINER INITIAL		DOG	CUME	NT NI	UMBE	R			DATE	NAME	CLASS	SUBCLASS		
	LA													
	LB													
	LC													
	LD													
	LE													
	LF													
	-1		<u> </u>		<u>•</u>		·	OREI	GN PATENT D	OCUMENTS				_
		DOG	CUME	NT N	UMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	TION
			į		YES	NO								
	I H													
	<u>,</u>	. <u>.</u>			ОТНЕ	R PRIO	OR AR	T (Inc	uding Author,	Fitle, Date, Pertinent	t Pages, Etc.)			
	LI	Ama	ass et a	ıl., "Ef	ficacy	of dail	y and a	alterna	e-day dosing re			norphine-naloxon	e tablet"; Drug	g and
	IJ									and naltrexone in ra	ats";(1987) Vol	36, pp. 127-130.		
	LK	Jasii		al., "T	he hur	nan ph							nd Exper Ther	a (1967)
	LM	Jone		, "Nal	mefen	e:block			enous morphine	challenge effects in	opioid abusinh	humans"; Drug a	nd Alcohol	
	LN	Kan		l., "Cli	inical (Charate	ristics	of Nal	oxone-Precipita 5-363.	ted Withdrawal in F	łuman Opioid-I	Dependent Subjec	ts"; J Pharma a	and
	LO	Kin		, "Nalt	rexone	Biotra	ansforr	nation	and Incidence of	of Subjective Side En	ffects: A Prelim	inary Study"; Alc	oholism: Clin	and
	LP	Kog	an et a	1., "Es	timatio	on of th	he Syst	emic A	vailability and	Other Pharmacokino . And Pharm (1977)	etic Parameters	of Naltrexone in N	∕lan after Acut	e and
	LQ									oine-Abusing Heroir			(1994) Vol 1	. p 151.
	LR	Kos	ten et a							ine maintained patie				
	LS		land et	-		ne and	the Na	arcotic	Abuser: A Cont	trolled Study of Part	ial Blockade";	nter. J. of the Ado	lictions (1974)	Vol 9,
EXAMINER	<u>L</u>	No	5, pp. 6	003-67	72.				<u> </u>	DATE CONSIDE	ERED			
*EXAMINER:	Initial if	referen	ce con:	sidere	d, whe	ther or	not cit	ation is	s in conformanc	e with MPEP 609; I	Draw line throu	gh citation if not i	n conformance	e and not
considered. Inc														

FORM PTO-14 (REV. 7-80)	49							COMMERCE ARK OFFICE	ATTY. DOCKE 200.1134CON	Г NO.:	SERIAL NO.: 10/827,623		
	LIST O	F PRIOR A	ART C	ITED 1	BY AI	PPLIC	ANT		APPLICANT(S): Benjamin OSHL				
	(Us	se several sho	ets if r	necessa	ry)				FILING DATE: December 29, 20	003	GROUP: 1614		
							IIS	PATENT DOC				1	
*EXAMINER INITIAL		DOCUMI	ENT N	ИМВЕ	R	_	0.5.	DATE	NAME	CLASS	SUBCLASS	FILING DA	
	МА				ŧ								
	мв												
	MC												
	MD		 										
	ME		<u> </u>				- · · · -						
FOREIGN PATENT DOCUMENTS													
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION													
DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO													
		{											
	MG	<u>, , , , , , , , , , , , , , , , , , , </u>	<u> </u>	OTHE	R PRIO	OR AR	T (Incl	uding Author	Γitle, Date, Pertinen	t Pages, Etc.)	•		
	МН	•							vents Tolerance and	•	Anesth Analg (19	97) Vol 84, pp	o.810-
	MI					laloxon	e on th	ne Postoperative	: Analgesic and Res	piratory effects	of Buprenorphine	"; Eur. J. Clin	Pharm
		(1988) Vo											
	MJ								w-dose Naloxone";				
	MK	Loimer et (1991) Vo				oxone/I	Methac	lone Preparation	ns for Opiate Substi	tution Therapy"	; J. of Substance	Abuse Treatme	ent
	ML	Martin et Arzneim-	al. "Bi Forsch	oavaila /Drug	bility l Res. (1	Investig 999) V	gation o	of a New Tilidir pp. 599-607.	ne/Naloxone Liquid	Formulation Co	mpared to a Refe	rence Formula	tion";
	ММ	Martin et Thera (19						to and Physical	Dependence on N-a	allynormorphine	(Nalorphine)";J.	Of Pharm and	Exper
	MN	Mendelso	n et al.	, "Bupr	enorpl	hine an	d nalo	xone combinatio	ons: the effects of th	nree dose ratios i	n morphine stabil	ized, opiate-de	ependent
	МО	Mendelso	n et al.	, "Bupr	enoph	ine and			in Methadone Mai	ntenance Patien	ts"; Society of Bio	ological Psych	iatry
	МР	(1997) Vo					xture fo	or use in methad	done maintenance p	orograms"; Clin	Pharm and Ther.	Vol 15, No 2.,	pp 156-
EXAMINER	1	166							DATE CONSIDI	ERED			
BAAMINER									DATE CONSIDI				
*EXAMINER:									e with MPEP 609;	Draw line throug	gh citation if not i	n conformance	e and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKE 200.1134CON	T NO.:	SERIAL NO.: 10/827,623		
	LIST)F PR	IOR A	ART C	ITED	BY AI	PPLIC	ANT		APPLICANT(S) Benjamin OSHI				
	(Us	se seve	ral she	eets if i	necessa	ıry)				FILING DATE: December 29, 20	003	GROUP: 1614		
		,						U.S.	PATENT DOC	CUMENTS		,		
*EXAMINER INITIAL		DO	CUME	ENT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	NA													
	NB			<u> </u>			_							
	NC	<u> </u>		<u> </u>			ļ	ļ						
	ND			<u> </u>	<u> </u>			ļ						
	NE			<u> </u>			<u> </u>							
							F	OREI	GN PATENT D	OCUMENTS				
	DOCUMENT NUMBER DATE										CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	NF													
					ОТНЕ	R PRI	OR AR	T (Inc	luding Author,	Γitle, Date, Pertiner	nt Pages, Etc.)			
	NG		vatika 41-94		, "Metl	nadone	-nalox	one in	combination for	the Treatment of I	Heroin Addicts";	Clin. Pharm and	Thera, Vol 14,	, No. 6,
	NH		vartika 0-1354		., "Nal	oxone-	Methad	done C	Combination for	the Treatment of O	piate Dependenc	e"; Missouri Inst	itute of Psychi	atry, pp.
-	NI	Alor	et al. ne and	I in Co	nocice mbinat	ptive a ion wi	nd Res th Opic	ponse oid An	Rate-Altering E tagonists in Squ	ffects of Kappa Opirrel Monkeys"; J o	oioid Agonists, S of Pharm and Exp	piradoline, Enado oer Thera (1994)	oline and U69, Vol 271, No 3	593, , pp.
	NJ			al., "B o. 484-		orphine	and N	aloxor	ne alone and in	combination in Opi	oid-dependant H	umans"; Psychop	harmacology	(1988),
	NK						altrexor No 2 pj			romorphone and Pe	entazocine Effect	s in Human Volu	nteers"; J of P	harm and
	NL			al., "E o. 27-3		of Sub	lingual	ly give	n naloxone in C	pioid -dependant h	uman volunteers	"; Drug and Alco	hol Dependen	ce (1990)
	NM									orphine-Naloxone ne, pp. 145-149.	Combinations";	Dept of Psychiatr	y and Behavio	ral
	NN	Wil	kler et phine,	al., "N , metha	l-Allyli idone o	normor	phine: in in m	Effect an (po	s of single dose st addicts)"; N-	and Precipitation of Allylnormorphine I	of Acute "Abstine During Narcoctic	ence Syndromes" Addiction (1953)	during addicti) pp. 8-20.	on to
EXAMINER										DATE CONSID	ERED			
*EXAMINER:	Initial if	referen	ce con	nsidere	d, whe	ther or	not cit	ation is	s in conformanc	e with MPEP 609;	Draw line throug	gh citation if not i	in conformance	e and not
considered. Inc														

FORM PTO-14	49							OMMERCE RK OFFICE	ATTY. DOCKET	ΓNO.:	SERIAL NO.: 10/827,623		
(REV. 7-80)	LIST O	F PRI	OR AR	PATE T CITEE				KK OFFICE	APPLICANT(S): Benjamin OSHL		10/02/,023		
	(Us	se sever	al sheets	s if necess	sary)				FILING DATE: December 29, 20		GROUP: 1614		
							U.S. P	ATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	CUMEN	T NUMB	ER			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
	OA				$oldsymbol{\perp}$							 	
	ОВ										_	ļ	
	ос				↓	ļ							
	OD					$oldsymbol{ol}}}}}}}}}}}}}}}}}$							
	OE												
		ı				F	OREIGI	N PATENT D	OCUMENTS		1	1	
		DOC	CUMEN	T NUMB	ER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION _
												YES	NO
	OF												<u> </u>
				отн	ER PRI	OR AR	T (Includ	ding Author,	Title, Date, Pertinen	t Pages, Etc.)			
	OG	Zaks	et al., "	Naloxone	Treatn	nent of C	Opiate D	ependence";	JAMA (1971) Vol 2	15, No 13, pp. 2	2108-2110.		
	ОН	Bart	on, et al.	, "Intrana	sal Adr	ninistrat	tion of N	Valoxone by P	aramdeics";Prehosp	ital Emergency	Care (2002) Vol	6, No 1, pp. 54	1-58.
	OI	Blac	hly, Pau	1, H., M.I)., "Nal	loxone i	in Opiate	Addiction";	Current Psychiatric	Therapies (1976	o) pp. 209-213.		
	Oì			., "Relati 995) Vol				ntrolled-releas	e oral morphine sul	fate during naltr	exone blockade";	Inter J of Clin	Pharm
	ок	Jasir 258.		R., "Asses	sment o	of the Al	buse Pot	eniality of Mo	orphinelike Drugs (N	Methods Used in	n Man)"; Drug Ad	diction (1977)) pp. 197-
_	OL	John	ison et a	l., "Bupre	norphir	ne and N	Naloxone	for Heroin D	ependence"; Substa	nce Use Disord	ers (2000) pp. 519	9-526.	
	ОМ	Strai 217.		"Opioid a	intagon	ist effec	cts of dez	zocine in opio	id-dependent humar	ns"; Clin Pharm	and Thera (1996)) Vol 60, No 2	, pp. 206-
	ON	Pres 49-8		., "Abuse	liability	y and stu	udies of	opioid agonis	t-antagonists in hun	nans"; Drug and	Alcohol Depende	ence (1991) vo	ol 28, pp.
	00	Bren Tilid	nscheid line/Nale	t et al., "F oxone Sus	harmad stained	okinetio Release	ics of No Tablets'	rtilidine and I "; Arzeim-For	Naloxone after Adm sch/Drug Res. (200	inistration of Ti 0) Vol 50, pp. 1	lidine/Naloxone S 015-1022.	olution or	
EXAMINER									DATE CONSIDI	ERED			
*EXAMINER: considered. Inc									e with MPEP 609; 1	Draw line throu	gh citation if not i	n conformance	e and not

FORM PTO-144 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET 200.1134CON	NO.:	SERIAL NO.: 10/827,623		
	LIST O	F PRI	OR A	RT CI	TED 1	BY AP	PLIC	ANT		APPLICANT(S): Benjamin OSHLA	ACK et al.			
	(Us	se sever	ral shee	ets if n	ecessa	гу)				FILING DATE: December 29, 200	03	GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOC	CUME	NT NU	ЈМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
	RA													
	RB													
	RC													
•	RD						ļ							
	RE													
	RF							<u> </u>						
	RG													
	RH						<u> </u>							
	RI													
	R.J									· 				
"	RK													
	RL													
	RM													
	RN					<u> </u>								
							I	FOREI	GN PATENT D	OCUMENTS				
		DOC	CUME	NT NU	ЈМВЕ	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
	RO													
				(OTHE	R PRIC	OR AR	T (Inc	luding Author, 7	litle, Date, Pertinent	Pages, Etc.)			
	RP													
	RQ_	Phys	sician's	s Desk	Refer	ence (2	2001) s	ee Rev	via, pp. 1146-11	49 and Oxycontin, p	p. 2697-2701			
	RR _													
	RS						- ""							
EXAMINER					,					DATE CONSIDE	RED			
*EXAMINER: considered. Inc	Initial if i	referency of thi	ce cons	sidered with r	l, whet	her or	not cit	ation is	s in conformanc	e with MPEP 609; [Draw line throug	h citation if not i	n conformanc	e and not

			-						~~~ ~~~	T				
FORM PTO-144 (REV. 7-80)	9								F COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
		OF P				BY A	PPL R	CANT		APPLICANT(S): Benjamin OSHLACK et	al.			
	(Use	several	sheets	f neces	sary)				·	FILING DATE: December 29, 2003		GROUP: 1614		
								U.	S. PATENT DO	CUMENTS				
'EXAMINER INITIAL		DOC	CUMEN	T NUM	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	_
XX	ВА	3	9	1	6	8	8	9	11/04/1975	Russell	128	145.8		
JBL	ВВ	3	9	6_	5	2	5	6	06/22/1976	Leslie	424	22		
1 Ar	ВС	3	9	6	6	9	4	0	6/76	Pachter et al.	424	260		
XV	BD	4	1	7	6	1	8	6	11/79	Goldberg	424	260		
Jr.	BE	4	2	3	7	1	4	0	12/02/1980	Dudzinski	424	260		
BE 4 2 3 7 1 4 0 12/02/1980 Dudzinski 424 260 FOREIGN PATENT DOCUMENTS														
		DOC	UMEN	T NUME	BER			COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON		
YES NO														
XIL														
, 33/	BG	9	8	3	5	6	7	9	8/98	wo	A61K	31/485		
M	вн	9	9	3	2	1	2	0.	7/99	wo	A61K	31/485		
Jr.	ВІ	0	0	0	1	3	7	7	01/13/2000	WO	A61K	31/00		
RI	вл	8	7	0	1	2	8	2	03/12/1987	wo	A61K	31/485		
U					ОТ	HER P	RIOR A	RT (inc	fuding Author, Ti	tle, Date, Pertinent Pages,	Etc.)			
In	ВК	Chih-	Cheng	Chien,	et al., "S	Sigma /	Intagon	ists Pol	tentiate Opioid A	nalgesia in Rats", Neurosci	ence Letters 1	90 (1995), 137-139.		
In	BL	Crain Antin	et al., ' ocicepti	Ultra-Lo ve Pote	ow Con	centrati d Atten	ions of l uating T	Valoxor olerano	ne Selectively An xe/Dependence [lagonize Excilory Effects o During Chronic Cotreatmen	f Morphine on t." Proc. Nati. /	Sensory Neurons, 1	Thereby Increasi (5) 92:10540-10	ng Its 544.
gn	BN									mington's Science and Pra				
M	во								1994) Montvale,				-	
Su	вР									hine by Methylnaltrexone t	n Doas".J. Clin	Pharmacol (1993).	33:747-751	
m	BQ					•				s Intrathecal Morphine Anti				6-73
<u> </u>	- BR									nal Administration of Selec				
EXAMINER -	Tef.	Pres	É	5,0	ررح	اعد				DATE CONSIDERED	حمادم	25,2005		
*EXAMINER: Initia copy of this form w	l if referen ith next co	ce cons mmunic	idered, ation to	whethe	r or not ant.	citation	is in co	onforma	ince with MPEP	609; Draw line through cita	,			lude

BEST AVAILABLE COPY

					==		_	=		7				
FORM PTO-1449 (REV. 7-80))				-	•			F COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
	_) BY A	APPLIC	CANT		APPLICANT(S): Benjamin OSHLACK et	al	·		
	(Use s	several s	heets i	fneces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U	.S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	UMEN	T NUMI	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	_
BL	DA	4	5	7	3	9	9	5	3/86	Chen et al.	604	896		
132	DB	4	5	8	2	8	3	5_	4/86	Lewis et al.	514	282		
M	DC	4	6	0	8	3	7	6	8/86	Pastemak	514	282		
18W	DD	4	6	6	1	4	9	2	4/87	Lewis et al.	514	282		
Mr.	DE	4	7	1	9	2	1	5	1/88	Goldberg	514	282		
Nil.	OF 4 7 3 0 0 4 8									Portoghese et al.	546	45		
881	DF 4 7 3 0 0 4 8 DG 4 7 6 0 0 6 9								7/88	Rzeszotarski et al.	514	282		
								FOR/	EIGN PATENT D				<u> </u>	
		DOC	UMEN	T NUME	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	אכ
								.					YES	NO
	 	 	$\overline{}$	г—					 '					
A C	DH	0	1	9	3	8	5	2	12/31/2001	WO (A2)	A61K	31/00		
Jen .	DI	0	9	1	3	1	5	2	6/99	EP	A61K	31/485		
- AN	DJ.	0	6/	4	7	4	4	8	4/95	EP	A61K	31/485		
Jr.	DK	0	3	5	2	3	6	1	1/90	EP	A61K	31/485		
Xv.	DL	0	2	0	5	2	8	2	12/86	EP	A61K	9/22		
ļ		,			<u>01</u>	HER P	RIOR A	vRT (Inc	cluding Author, Tr	ide, Date, Pertinent Pages,	Etc.)		·	
	OM	Alavn	ez-Fuer	ntes, el	21. E#	ectiven:	occ of F	lepeate	d Administration	of a New Ora Natirexone C	Controlled-Rele	e sse Systom in Mo q	phine Analgesia	;ı.
					2001), 5									
	N									elease Naltrexone Complex				
	,00									elopment of Naturexone', N				
	OP-	Baum	et al.,	The in	pact of	the Add	dition of	Nalox	one on thr Use ar	nd Abuse of Pentazocine";	Public Health	Reports (1987) Vol.	102, Νο. 4 ρ. 42	6-429.
7	DQ									search Monograph 147 (199				
	DR.	-Bloon 1349.		*Clinica	al Studio	es with	Natoxor	nemetr	lacione in a Ratio	o of 1:20°, 5 th National Conf	ference on Me	thadone Treatment	(1973) Vol 2, p.	1342-
EXAMINER	Tef	fre	E	. Nu	DSc	(DATE CONSIDERED	Janus	25, 2	.005.	
*EXAMINER: Initial copy of this form w	I if referen	ce cons	idered, cation t	wheth:	er or not	t citatio	n is in ç	onform	ance with MPEP	609; Draw line through cita				atude

FORM PTO-1449						e ne	PADTIA	-NT N	F COMMERCE	ATTY, DOCKET NO.:		SERIAL NO.:		
(REV. 7-80)									MARK OFFICE	200.1134CON		10/747,865		
·				ART	•	BY A	PPLI	CANT		APPLICANT(S): Benjamin OSHLACK et	al.			
	(Use s	everal (sheets i	if neces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U.	S. PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DOC	UMEN	TNUM	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
RM	EA	4	7 :	6	9	3	7	2	9/88	Kreek et al.	514	282		
Son	EB	4_	7	8	5	0	0	0	11/88	Kreek et al.	514	282		
No.	EC	4	8_	0	3	2	0	8	2/89	Pasternak	514	282	-	
m	EO	4	8	0	6_	3	4	1	-2/89	Chien et al.	424	448		
32	EE	4	8 0 6 5 4 3 2/89 Choi 514 464											
87V	EF	4	8 0 6 5 4 3 2/89 Choi 514 464 8 0 6 5 5 8 2/89 Wuest et al. 514 381											
1911	EG	4	8	2	8	8	3	6	05/09/1989	Elger et al.	424	419		
-,								FORE	EIGN PATENT D	OCUMENTS				
		DOC	UMEN	T NUM	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	N N
								i		•			YES	NO
Jan .					Γ_	Γ_	Γ.	<u> </u>						
Ko.	EH	0	1	9	3	3	5	5	09/03/1986	EP (A3)	A61K	31/615		
Q vi	El	0	3	1	9	2	4	3_	06/07/1989	EP (A1)	A61K	31/485	•	
020	EJ	0	3	1	9	2	4	3	11/07/1990	EP (81)	A61K	31/485		
0	EK	19	6	5	1	5	5	1	6/98	DE	A61K	31/485		<u> </u>
100	EL	29	7		9	7	0.	4	2/97	DE	A61K	31/485	x	
	-	·			01	HER P	RIOR A	RT (Inc	auding Author, Ti	tle, Date, Pertinent Pages,	Etc.)			
	-EM	Briso	oe et a	., Mei	ociocin	hamox	Time C	ourse t	of Changes in All	euranii-Reinforced Rhesus	Monkeys; Ps	/chopharmacology	(2000) 148.393	399
	EN	- Abstr	act of E	homing	et al., 1	A Sensi	live Me	thod to	Evaluate Effects	of Analgesics in Man"; Me	th and Find Eq	oll Clin Pharmacol ((8) (1083) p. 5	15-551.
	EO.	Builin	gham e	a a., (ilnical l	ीवाराम	coldnet	CS Of N	arcode Agonist-A	ntagonisi Drugs', Clinical	Pham (1983) र	332-343.		
	_EP	Calin	lim, et . 6-564.	al Fffe	ct of Na	doxone	on the	Analge	sic Activity of Me	thadone in a 1:10 Oral Cor	mbination, Clin	Pharmacol and Th	ere (1974) Vol.	15; No. 6
	FO.			-"Meth	adone :	and Nas	OYOTE I	Come	manon (Namone	e) for the Treatment if Her	nto Addictor D	soinstande Llatei	nn 1336.1341F	
J	EK							_	96) May:51 (5) p		Cai Addices , B	Stor Estational R.S.	W.1350-13411 .	
	ES ES									se Preparation ; Drug and	Alegara Cara	Annov4400C) 4C -	n 1 8	
EXAMINER		Guar	y, e. a	. Cisuc	ai cvai	Jauon U	a Nau	IEXUIE	Sustaineu-Relea		Acutoi Deper	dence (1505) 16, p	9.1-8	
- Anninter	F ST	G	F	he	<i>ع</i> د					DATE CONSIDERED	T	25.0	700	1
#EVALUATED 1. 22	, — <u>, , , , , , , , , , , , , , , , , ,</u>	7	<u>U</u> ,			<u></u>						22,5		
"EXAMINER: Initial copy of this form wi	u referen Uh next co	ce cons Immuni	idered, ation t	wnetho o applic	er or not eant.	t citation	n is In c	onforma	ince with MPEP	609; Draw line through cita	ation if not in co	nformance and not	considered. Inc	tude

FORM PTO-1449 (REV. 7-80))								F COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
,	LIS	T OF PI	RIOR	ART (CITED	BY A	PPLIC	CANT		APPLICANT(S): Benjamin OSHLACK et	al.			
	(Use	several s	heels if	neces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U.	S. PATENT DO	DUMENTS				
*EXAMINER INITIAL		DOCU	MENT	NUMB	ER				DATE	NAME	CLASS	SUBCLASS	FILING DATE	
MV.	FA	4	8	3	4	9	6	5	05/30/7989	Martani et al.	424	488		
You	FB	4	8	3	4	9	8	4	05/30/1989	Goldie et al.	424	488		
\$ P	FC	4	8	3	4	9	В	5	05/30/1989	Elger et al.	424	488		
831	FD	4	8	4	4	9	0	7	07/04/1989	Elger et al.	424	465		
Stel	FE	4	8	4	4	9	0	9	07/04/1989	Goldie et al.	424	480		
M	FF	4 8 4 4 9 1 0 07/04/1989 Leslie et al. 424 494 4 8 6 1 5 9 8 8/89 Oshlak et al. 424 468												
Ser	FG	FG 4 8 6 1 5 9 8 8/89 Oshlak et al. 424 468												
		4 8 6 1 5 9 8 8/89 Oshlak et al. 424 468 FOREIGN PATENT DOCUMENTS												
		DOCU	MENT N	IUMB	ER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	N
										·			YES	NO
M.	FH	4	3	2	5	4	6	5	2/95	DE	A61K	31/485		х
m	FI	2	2	2	2	0	3	9	11/72	DE	A61K	27/00		
ASI	FJ.	9	8	2	5	6	1	3	06/18/98	wo	A61K	31/485	abstract	
SW	FK	0	0	3	8	6	4	9	07/06/00	wo	A61K	9/00	ábstract	
U					01	HER P	RIOR A	RT (Inc	tuding Author, Ti	itle, Date, Pertinent Pages,	Etc.)			
	J.	Chilang	etal, 1	Cinetic	Solat	taltrexo	ne Susi	ained-f	Release Preparat	ion*, Clin Pharmacel Thera	(1984) Vol 36	No. 5, pp.704-708.		
	FM.									lects Of Heroin un Humans				_
	ĘN.									nist; Clinical Pharmacy, Vo				
	FO	Crain e	tal., "Ar	ntagon	ists of E	xcitato	y Opioi	id Rece	ptor Functions E	nhance Morphine's Analge Pain 82 (1999)pp.1-11.			Tolerance/depe	ndence
	FP	Crain e	tal., "Ar	itagon	ists of E	xcitato	y Opici	d Rece	plor Functions E	nhance Morphine's Analge Pain 84 (2000) pp.121-13	sic Potency an	d Attenuate Opioid	Tolerance/depe	ndence
	£Ω									s. Vd 9, No. 5;pp.568-577.				
	TR									Dependent Meri"; J. Phar	m And Evec	Thorn (6072) (-2		
EXAMINER _	Te f	, C	E,			A	<u>ше-1,0</u>	- Aur	Office & Natcoli	DATE CONSIDERED		75,20		00.
*EXAMINER: Initia copy of this form w		nce cons	idered, v	whethe	er or no	<u> </u>	n is in o	onform	ance with MPEP	609; Draw line through cita				dude

FORM PTO-1449 (REV. 7-80)									F COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 200.1134CON		SERIAL NO.: 10/747,865		
		OF P		•		BY A	PPLIC	CANT		APPLICANT(S): Benjamin OSHLACK (et al.			
	(Use	several	sheets i	f neces	sary)					FILING DATE: December 29, 2003		GROUP: 1614		
								U.	.S. PATENT DO	CUMENTS				
*EXAMINER INITIAL		DOG	UMEN	T NUM	BER				DATE	NAME	CLASS	SUBCLASS	FILING DATI	
m	GA	4	8	6	1	7	8	1	8/89	Goldberg	514	282		
SIL.	GB	4	8	6	7	9	8	5	09/19/1989	Heafield et al.	424	461		
M.	GC	4	8	7	3	0_	7_	6	10/89	Fishman et al.	412	10		
35L	GD	4	8	8	2	3	3	5	11/89	Sinclair	514	282		
W.	GE 4 8 8 9 8 6 0 12/89 Rzeszotarski et al. 514 282 GF 4 9 3 5 4 2 8 6/90 Lewis 514 282													
M														
Jun-	GG	4	9	4_	0	424	480							
U	GG 4 9 4 0 5 8 7 07/10/1990 Jenkins et al. 424 480 FOREIGN PATENT DOCUMENTS													
		000	UMEN'	T NUMI	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
													YES	МО
XI	GH	00	1_	5	8	4	7	7	8/16/01	wo	A61P		abstract	
0	-				01	THER P	RIOR A	VRT (Inc	cluding Author, T	itle, Date, Pertinent Page	s, Etc.)			
	GI	Fras	er, Albe	rt D., el			-			Treatment of Opiate Depe		al Toxicology I (199	10) Val 10, No. 2;	pp.375-
7	GJ	Frey	e el al.,	Effects	s of Tra	madol a	and Tilic	line/Na	loxone on Oral-C	aecal Transil & Pupillary	ight Reflex': Ar	Zneim-Forsch/Droo	Res. 50(1)(2000)	00, 24-30.
	GK-	Į.								ne-Stabilized Opiold Addi				
	GL									nefene"; Clin Pharm and 1				
	GM	1								ne ; Clin Pharm and Ther				
	GN	'								realment of Heroin Addict			nt (1995) Vol 12.	1, pp. 35-
	GO	Ghod	lse, et a	d., "Opi	oid ana	lgesics	and Na	rcotic A	Intagonists"; Side	Effects of Drugs (2000)	Annual 23, chpt	8 pp. 96-113.		
EXAMINER J	eff	~	Ξ, ι							DATE CONSIDERED	Jan		,2005	
*EXAMINER: Initia	al if refere	nce con	sidered	, wheth	er or no	t citatio	n is in c	onform	ance with MPEP	609; Draw line through ci				clude

FORM PTO-14 (REV. 7-80)	149							-	COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	io.:	SERIAL NO.: 10/747,865		
	LIST	OF PR	IOR A	RT C	ITED I	BY AI	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	CK et al.			,
	(U	se seve	ral sho	ets if n	ecessa	ry)				FILING DATE: December 29, 2003	·	GROUP: 1614		
	· · · · · · ·							U.S.	PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DO	CUME	NT N	ЛМВЕ	R		·	DATE	NAME	CLASS	SUBCLASS	FILING DA	
8h	HA	4	2	0	0	0_	9	8	04/29/1980	Ayer, et al.	128	260		
m	НВ	4	9	7	0	0	7	5	11/13/1990	Oshlak	424	451		
m	нс	4	9	8	7.	1	3	6	01/22/1991	Kreek et al.	514	282		
pr	HD	4	9	9	0	3	4		02/05/1991	Goldie et al.	424	484		
M	HE	5	0	7	1	6	4	6	12/10/1991	Malkowska et al.	424	497		
yr	HF	5	0	7	5	3	4	t.	12/91	Mendelson et al.	514	282		
M	HG	5	0	8	6	0_	5	8	2/92	Sinclair et al.	514	282		
							F	OREK	ON PATENT D	OCUMENTS				
		DOC	CUME	NT N	JMBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	МО
KU	нн	00	1	8	5	1	5	0	11/15/01	wo	A61K	31/00		
	, .				OTHE	R PRIC	R AR	r (Incl	uding Author, T	litle, Date, Pertinent Pa	iges, Etc.)			
	H	Otat	, Will	iam, M	.D. FA	CP, "	A New	Metho	d for Detoxifyi	ng Opoiod-Dependent	Patients"; J.	Substance Abuse	Treatment (19	99)
		Vol.	17, No	.3,pp.	193-19)7			·	·		· · · · · · · · · · · · · · · · · · ·		
	10	Gold	, et al.	."Rapi	d Opio	id Det	oxifica	tion D	uring General A	nesthesia"; Anesthesia	ology (1999)	Vol 91, No 6, pp.	1639-1647.	
	HK	Gree (199	nwald 6) Vol	<u>. ct al.</u> 277, ì	"Com lo 3, p	paratis p. 122	e Clin 8-1236	ical Ph	armacology of (Short-Acting µv Opioi	ds in Drug Al	ousers"; J. Pharm	and Exper Th	ıcra
	HL_	Gup	la , et a	l., "M o	rphine	Com	ined v	nth Do	xapram or Naic	xone'; Anesthesia (19	74) Vol.29, p	p. 33-39.		
	нм	Rich Res.	ter et a	ol., "Cl o II)(19	inical I 985)pp	nvesti . 1742	gation. -1744.	on the	Development o	E Dependence during C	onl Therapy	with Tramadol";	Arzniem-Fors	ch/Drug
	HN	Rose		., 'The				ne on 1	Valoxone-precip	vitated Opiate withdray	val"; Drug an	d Alcohol Depen	dence (1998)	Vol 52,
	но	Rose	n et al			ıdy of	Dextre	metho	phan in Nalox	one-Precipitated Opiate	Withdrawat	, European I of	Pharm. (1996) Vole
EXAMINER	^	\	<u> </u>	231						DATE CONSIDERE	·n			
	Je-	Fre	16	E. R	وكدن	1	_				_	25,20	105	
*EXAMINER: I considered. Incl	nitial if n	eference of this	e cons	idered	wheth	er or r	ot cita	tion is	in conformance	with MPEP 609; Drav		1		and not

FORM PTO-14- (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	0.:	SERIAL NO.: 10/747,865		
•	LIST O	F PRI	OR A	RT CI	TED I	3Y AP	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	K et al.			
	(Us	e seve	ral shee	ets if no	ecessar	y) 				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS				
*EXAMINER INITIAL		DOG	CUME	NT NU	ЈМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
M	IA	5	0	9	1		8	9	02/25/1992	Heafield et al.	424	457		
Skr	ıB	5	0	9	6	7	1	5	3/92	Sinclair	424	449		
XV	IC	5	1	0	2	8	8	7	4/92	Goldberg	514	282		
3h	ID	4	ī	6	0	0	2	ő	07/03/1979	Ayer, et al.	424	15	-	
XV	IE	5	ī	4	9	5	3	8	9/92	Granger et al.	424	449		
XI	IF	5	2	1	5	7	5	8	06/01/1993	Krishnamurthy	424	488		
XV	IG	5	2	2	5	4	4	0	7/93	London et al.	514	535		
- V														
FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION VES. N														пои
]	50	COMIL				YES	NO						
No.		ļ	1				γ -	ı	<u> </u>	·	 			
1	ш	00	0	6	7_	7	3	9	11/16/00	wo	A61K	31/00	<u>l</u>	i
		/								Title, Date, Pertinent P				
	ע	Sch	uh et a	l., "Bu ra (199	prenor	phine.	Morpl	nine an	d Naloxone Eff	ects during Ascending	Morphine Ma	aintenance in Hur	nans"; J. Phan	n and
	iK .	7								lockade Produced by E	unrenombine	and Naltrexone	in Humans":	
	1.5	Psy	chopha	rmaco	logy (1	999) \	/ol 14	5, pp.	162-174.					
	11-									e: Reverse-Order Preci	pitated With d	rawal and Dose-I	Dose Interaction	ns':
	74								10-211.	ms by Cocaine Abuse	ducing Metha	done and Runren	ombine Maint	enance":
	M	Am	. J. Dn	, Keo 1g and	Alcoh	ol Abu	se (19	94) Vo	il 20, 4, pp. 445	458.	sormy rate ma	uone and Duprem	Orphine Walle	
	N_	Stin	o ct al.	, Use	of Dr	ig Con	nbinati	ons in	Treatment of O	piopd Withdrawal"; J.	Clinical Payo	h (1992) Vol 12,	No 3, pp. 203	-209.
	10	Stol	ler et a	I., "Ef	fects o	f bupre	norph	inc/nal	loxone in opioid	-dependent humans" F	sychopharma	cology (2001) Vo	ol 154, pp. 230	-242.
	IP ~	Stra	in ct a	i., "Ac ı	ate Eff	ट्टाड ठा	Bupre	norph	ine, hydromorpi	none and natoxone in n	nethadone-ma	intained volunter	as"; J. Pharm	and
	+	7		ra (199									'. Dauchanhan	nacolom;
	10	1		1. "EŒ 1 148, j		-	no up hi	ne ven	sus buprenosphi	ne/naloxone tablets in	non-depender	it optoto abusers	, rsychopham	IMCOIORA
	IR			I., "Pre , pp. 62			hdraw	al by F	entazocine in M	Lethadone-Maintained	Volunteers";	J. Pharm and Exp	per Thera (199	3) Vol
	ls.	7					ntagon	ist The	rapy for Heroin	Addiction"; NIDA (19	97) 5 pages			
EXAMINER	To			E,						DATE CONSIDER	ED.	m 25,	2005	
*EXAMINER:										e with MPEP 609; Dr	aw line throug	gh citation if not i	in conformance	e and not

FORM PTO-14	49		·						COMMERCE	ATTY. DOCKET N	IO.:	SERIAL NO.:		
(REV. 7-80)	LIST	AE DD	4 au				•		ARK OFFICE	200.1134CON APPLICANT(S):		10/747,865	·····	
							PPLIC	ANI		Benjamin OSHLAC	K et al.			
-		se seve	Tai she	ets if n	ccessa	ry) 				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DO	CUME	NT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
m	JA	5	2	2	6	3	3	1	07/13/1993	Thompson et al.	73	865.9		
Mr.	JB	5	2	3	6	7	1	4	8/93	Lee et al.	424	449		
pr	JC	5	2	5	6	6	6	9	10/93	Askanazi et al.	514	282		
M	JD	5	2	6	6	3	3	1	11/30/1993	Oshlak et al.	424	468		
YEN	JE	5	2	7	3	7.	6	0	12/93	Oshlak et al.	424	486		
ML	JF	5	2	8	6	4	9	3	02/15/1994	Oshlak et al.	424	468		
yw.	JG	5	3	1	6	7	5	9	12/93	Rose et al.	424	10		
<u> </u>		,					F	OCUMENTS						
		DOG	CUME	NTN	лмве	R		COUNTRY	CLASS	SUBCLASS	TRANSLA	TION		
	,											.	YES	МО
'XV	JH	00	0	5	1	5	9	2	9/05/00	wo	A61K	31/14		
₹ U	1				THER	PRIC	R AR	T (Incl	uding Author, T	itle, Date, Pertinent Pa	iges, Etc.)			
	11_	400	a a	ia ka	Valled	onest	ortene	d opio	Lasteria de la composición	with buprenorphine	Drug and A	leehel Dependenc	e (1999) Vol	56 pp.
		181-	190											
	JK U						•			2000) pp. 1975-2034.				
	JL V	Wan depe	g et al. ndence	<u>."Inve</u> "; J. N	rse Ag leuroch	onists remistr	and no ry (200	e lettel a 1) Vol	ntagonists at µ . 77, pp. 1590-1	opioid receptor (MOR) 600.	· possible rol	e of basal recepto	r signaling in	narcotic
	JM									pendence"; Annals Ne	w York Acad	emy of Sciences.	pp. 252-261.	
	N L									nalgesics"; Clin Pharm				
	10	Well	s, et al.	, " l n v	ivo Ph	armaco	ologica	l Char	acterization of S	SoRI 9409, a Nonpeptie	dic Onioid u	Agonist/δ-Antag	onist that Proc	luces
		Limi	ted An 97-60:	tinocic	eptive	Tolera	ince an	d Atte	nuates Morphio	ne Physical Dependent	ce"; J. Pharm	and Exper Thera	(2001) Vol.2	97. No 2,
	JP V				ur Tic	autični	for O	oloid E	Dependence": A	ustralian Prescriber (20	01) Vol 24 1	No.1 nn 4-6		
	JQ	1								ted naloxone-precipita			ose of methad	ione":
		Drug	and A	lcohol	Depen	dence	(1991)) Vol 2	7, pp. 139-148.	THE PERSON NAMED IN	THE STATE OF THE S	n. may a single-o	OJO OT TROUISE	>
	JR /	Zhu NMI	et al" OA reco	Naltre ptor a	xono-p ntagon	rocipit ists"; I	atod m Psycho	orphi n pharm	e-withdrawal in acology (2000)	infant rat is attenuated Vol 150, pp. 325-336.	Lby scute ad	ministration if NC	S inhibitors t	out not
EXAMINER _	r (DATE CONSIDERE	D			
	احإ	Tre	, 1	F. Re	szję					Janus	~ 25	,2005		
*EXAMINER: Inconsidered. Inch	itial if re	eference of this	(e consi form v	dered, with ne	wheth	er or n	ot cital	tion is to appl	in conformance	with MPEP 609; Draw	v line through	citation if not in	conformance	and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	0.:	SERIAL NO.: 10/747,865		
	LIST (OF PR	JOR A	RT C	TED	BY AI	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	K et al.			
	(U:	se seve	eral she	ets if n	ecessa	ry)				FILING DATE: December 29, 2003		GROUP: 1614		
	•							U.S.	PATENT DOC	CUMENTS				
*EXAMINER INITIAL		DO	CUME	וא דא:	JMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
m	KA	5	3	1	7	0	2	2	5/94	Borsodi et al.	514	282		
m	КВ	5	3	2	1	0	1	2	6/94	Mayer et al.	514	25		
XV	KC	5	3	2	4	3	5	1	06/28/1994	Oshlak et al.	106	153		
m	KD	5	3	3	6	6	9	1	08/09/1994	Raffa et al.	514	629		
8n	KE	5	3	5	2	6	8	0	10/94	Portoghese et al.	514	279		
XV	KF	5	3	5	2	6	8	3	10/94	Mayer et al.	514	289		
SKV	KG 5 3 5 6 4 6 7 10/18/1994 Oshlak et al. 106 153 FOREIGN PATENT DOCUMENTS													
0	FOREIGN PATENT DOCUMENTS													
	FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION													
101				<u></u>	1		_						TES	NU .
XYC	КН	0	1	5	8	4	5	1	08/19/2001	WO (A1)	A61K	31/485		L
U				(THE	PRIC	R AR	T (Incl	uding Author, T	litle, Date, Pertinent Pa	ges, Etc.)	·		
	KI	Han	ct al.,	"Muc e	oadhc	sive bu	ccal di	sks to	r novel nalbuphi	ine prodrug controlled	delivery; effe	ct of formulation	variable on dr	ug
	ĸ									narm (1999) Vol 177, p				
										(1983) Vol 12:7, pp. 4			.	
•	*K	Harr Drug	is et al g and A	. "Hur Alcohol	Deper	obine a ndence	nd Na l (2000	exone) Vol (-co-administrati 51, pp. 85-94.	on in opiate depende nt	patients stab	ilized on sublingu	al buprenorph	ine";
	KL									xone on intestinal tran	sit in volunte	ers taking codeine	": Aliment Ph	arm
		Ther	(2001) Vol 1	5, pp.	625-63	30.		· · · · · · · · · · · · · · · · · · ·					
_	KM									nd bromfenat in exper			ndomized cro	ssover
	KN									arm and Thera (1999)				
1										e's Clinical Anesthesic	-			
J\	KO-	incre	asing i	ts anti	nocice	enecni ptive p	otency	and a	tenuating tolera	ly entegonize excitator ince/dependence	y effects of n	norphine on senso	ry neurons, th	ereby
	W/	Hoy	es et a	., "The	Pharr	nacolo	gy of 7	R510	9, a new Narcoti	ic Agonist/Antagonist	Analgesic"; N	IIDA Research (I	979) pp. 99-10	05.
	KQ-	Lccli		l. <u>, "Di</u>	spositi					n the rat, dog, and mai				
EXAMINER -	τ									DATE CONSIDERE	D			
	<u> </u>	Hre	1 E	5, L	v .5 5	el	····				Jan	25.	2005	
*EXAMINER: In	nitial if re	eferenc	e cons	idered,	wheth	er or n	ot cita	tion is	in conformance	with MPEP 609; Drav		,		and not

FORM PTO-14 (REV. 7-80)	49								COMMERCE ARK OFFICE	ATTY. DOCKET N 200.1134CON	0.:	SERIAL NO.: 10/747,865		
	LIST ()F PRI	OR A	RT CI	TED	BY AF	PLIC	ANT		APPLICANT(S): Benjamin OSHLAC	K et al.			·
	(U:	se seve	ral she	ets if n	ecessa	(y)				FILING DATE: December 29, 2003		GROUP: 1614		
								U.S.	PATENT DOC	UMENTS		, , _		
*EXAMINER INITIAL		DOC	CUME	NT NI	ЛМВЕ	R			DATE	NAME	CLASS	SUBCLASS	FILING DA IF APPROP	
, An	LA	5	3	5	6	9	0	0	10/94	Bihari et al.	514	282		
XX.	LB	5	3	7	6	6	6	2	12/94	Ockert	514	282		
Xr.	ıc	3	5	4	ı	0	0	5	11/17/1970	Strathmann, et al.	210	19		
XX	LD	5	4	1	ι	7	4	5	05/02/1995	Oshlack et al.	424	456		
AL.	LE	5	4	2	6	1	1	2	06/95	Zagon et al.	514	282		
M	LF	3	5	4	1	0	o	6	11/17/1970	Bixler, et al.	210	23		
Xi.	LG	5	4	5	7	2	0	8	10/95	Portoghese et al.	546	35		
		•					F	ORFI	ON PATENT D		1			
		DOC	UME	NT NL	МВЕ	R	-		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	TION
		ļ											YES	NO ·
M	LH	0	8	8	0	3	5	2	02/03/1998	EP (B1)	A61K	31/485		x
U					THE	R PRIC	R AR	T (Incl	uding Author, 7	litle, Date, Pertinent Pa	iges, Etc.)			
	ш	Ama Alco	ss et a hol De	l ., "Eff pender	icacy (of daily 000) V	y and a	iternat	e-day dosing re	gimens with the combi	bation bupter	orphine-naloxon	e tablet"; Drug	and
	<u>ل</u>									and naltrexone in rats'	71987) Vol	t ri no 132 130		
_	LK	Jasin	ski et :	*	ic hun	an pha	-			ial of N-allylnoroxyme			nd Exper Them	(1967)
	ĹM							• .						= -
	LM	Depe	ndeno	. "Nain e (200	nerene O) Vol	60, рр	.29-37	intrave	nous morphine	challenge effects in op	ioid abusinh	humans"; Drug a	nd Alcohol	
	LN	Kano Expe	f et al.	, "Clin a (1992	ical C 20 Vol	haratea 260. 1	istics	of Nate	oxone-Precipitat 5-363.	ed Withdrawal in Hun	un Opi oid <u>-D</u>	ependent Subject	s"; J Pharma a	nd
1	LO_	King	ct al.		cxono	Diotra	nsforn	ration :	and Incidence of	PSubjective Side liffee	ts: A Prelimi	nary Study"; Alco	oholism: Clin a	nd
	IP_	Koge	n ct al	., "Esti	mado	of the	Syste	mic A	vailability and (Other Pharmacokinetic	Parameters o	f Naltrexone in M	lan after Acute	and
		Chro	nic Or	al Adn	rinistra	tion";	Res. (Comm.	In Chem. Path.	And Pharm (1977) Vo	118, No. 1, p	p 29-34.		
	W									ine-Abusing Heroin A				
	LR_	Koste 73-78		σΩ"	ioid ar	tagoni	st cha	lenges	in buprenorphi	ne maintained patients'	"; Drug and A	Alcohol Dependen	ice (1990) Vol	25, 00.
	LS			al., 'Na 63-672		e and t	he Na	rcotic A	Abuser: A Contr	olled Study of Partial l	Blockade"; In	ter. J. of the Add	ictions (1974)	Vol 9,
EXAMINER	Je	Fre	21 6	Z. 8	ردي	sel				DATE CONSIDERE		25	,2005	
*EXAMINER: In considered. Inclu										with MPEP 609; Drav			conformance	and not

Sheet 13 of 24

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE										ATTY. DOCKET NO.: SERIAL NO.: 10/747,865				
	LIST C			-			PLIC	APPLICANT(S): Benjamin OSHLACK et al.						
	(Us	e seve	ral she	ets if n	ecessa	ry) 				FILING DATE: GROUP: December 29, 2003 1614				
U.S. PATENT DOC										CUMENTS				
*EXAMINER INITIAL		DO	СИМЕ	NT NU	ЈМВЕ	R		**************************************	DATE	NAME	CLASS	SUBCLASS	FILING DA	
RU	MA	5	4	6	0	8	2.	6	10/24/1995	Merrill et al.	424	470		
. Ser	МВ	5	4	7	2	7	1	2	12/05/1995	Oshlack et al.	424	480		
Kin	МС	5	4	7	2	9	4	3	12/95	Crain et al.	514	12		
M	MD	5	4	7	8	5	7	7	12/26/1995	Sackler et al.	424	489		
YIL	ME	5	4	8	6	3	6	2	1/96	Kitchell et al.	424	426		· · ·
m	MF	5	5	0	0	2	2	7	03/19/1996	Oshlack et al.	424	476		
0			•				F	OREI	ON PATENT D	OCUMENTS				
		DOC	CUME	NT NU	MBE	R			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA	TION
													YES	NO
MG										l				
	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)													
	МН	815	ct al., *	Nalbu	phine (Coadm	inister	ed with	h Morphine Pre	vents Tolerance and D	ependence";	Anesth Analy (19	97) Vol 84, pr	.810-
	мі 🖊	<u>Lehr</u> (198	nan, et 8) Vol	al"In 34, pp	fluenc . 343-3	e of Na 352.	loxon	e on th	e Postoperative	Analgesic and Respire	atory effects o	of Buprenorphine	'; Eur. J. Clin	Pharm
XI	MJ	cviعار	ne et a	l., "Pot	entiati	on of F	cntazo	cine A	nalgesia by Lo	w-dose Naloxone"; J C	Jin Invest (19	988) Vol 82, pp. 1	574-1577.	
	WK	Loin	ner et a		mbine	d Nalo				s for Opiate Substituti				nt
	ML	Mart	in et a	l. "Bio:	availab	ility Ir	vestig	ation o	f a New Tilidin pp. 599-607.	e/Nalozone Liquid Fo	mulation Co	mpared to a Refer	ence Formula	tion";
	мм	Mart	in et al	"Der	nonstr	ation o	f Tole	rance t		Dependence on N-ally	normorphine	(Nakorphine)";J. (Of Pharm and	Exper
	мм	Mone	delson	5) Vol et al., '	Bupre	nomh	ine and	Lnalox	one combinatio	ns: the effects of three	dose ratios i	morphine stabili	zed, opiate-de	pendent
		volu	iteers"	; Psyct	ophan	macolo	igy (19	99) V	ol 141, pp. 37-4	6.				
	MO	Meno (199	delson 7) Vol	et al 41, pp.	Bupr. 1095	20phi 1101.	ne and	nelox	one Internetions	in Methadone Mainte	nance Patient	s"; Society of Bio	logical Psychi	atry
	MP	Nutt 166	ct al.,	'Metha	done-	азюже	n o mi x	ture fe	r use in method	one-maintenance-prog	rams"; Clin F	harm and Ther. V	'ol 15, No 2.,	рр 156-
EXAMINER (Je-	Fra	27	E_{l}	Ru	عدي	f			DATE CONSIDERE	ته کاچ	way 25	,2005	
*EXAMINER: is considered. Incl	nitial if re	ference of this	e cons	idered,	wheth	er or n	ot cita	tion is	in conformance	with MPEP 609; Dra			conformance	and not

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE									ATTY, DOCKET NO.: SERIAL NO.: 10/747,865						
	LIST						PPLIC	APPLICANT(S): Benjamin OSHLACK et al.							
	(U:	se seve	ral she	ets if r	necessa	шу)				FILING DATE: GROUP: 1614					
	U.S. PATENT DOC													·····	
*EXAMINER INITIAL		DO	CUME	NT N	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
Su	NA	5 5 0 2 0 5 8							3/96	Mayer et al.	514	289			
SW.	NB	5	5	0	8	0	4	2	04/16/1996	Oshlack et al.	424	468			
1000	NC	5	5	0	8	0	4	3	04/16/1996	Krishnamurthy	424	484			
JUL	ND	5	5	1	2	5	7	8	4/96	Crain et al.	514	282			
yw	NE	5	5	<u>L.</u>	4	6	8	0	5/96	Weber et al.	514	249			
· · · · · · · · · · · · · · · · · · ·					·		F	OREK	GN PATENT D	OCUMENTS					
	DOCUMENT NUMBER DATE									COUNTRY	CLASS	SUBCLASS	TRANSLAT	ПОИ	
													YES	МО	
	NF												-		
	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) NG Parwatikar et al., "Methadone-naloxone in combination for the Treatment of Heroin Addicts"; Clin. Pharm and Thera, Vol. 14, No. 6, pp 941-948.														
	NHS	Parw 1350	artika 1-1354	r et al.,	"Nalo	xone-N	/lethad	one Co	ombination for t	he Treatment of Opiate	e Dependence	e"; Missouri Instit	ute of Psychia	try, pp.	
	NI Pitts et al. "Antinociceptive and Response Rate-Altering Effects of Kappa Oploid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys"; J of Pharm and Exper Thera (1994) Vol 271. No 3. mg														
	lи	Prest	-1508.		prener	phine:	and Na	loxon	e alone and in co	ombination in Opioid-	lependant Hu	imans"; Psychopl	armacology (I	988),	
	NK ,	Prest	on et a		Ferenti	el Nel 264. N	rexono	- Anta;	gonism of Hydr	omorphone and Pentaz	ocine Effects	in Human Volun	teers"; J of Ph	arm and	
	NL	Prest	on et a		ects of					riold -dependant huma	n volunteers"	Drug and Alcoh	ol Dependence	(1990)	
	N M \	Bigel	ow et a	al., "Al	ouse Li	ability kins U	and A	ssessn ty Sch	ent of Bupreno	rphine-Naloxone Com	binations"; D	tept of Psychiatry	and Behaviors	ıJ	
	NN T	Wiki	er et a	I., "N-2	Allylnö	rmorp	une: E	fiects	of single dose a	nd Precipitation of Acu llylnormorphine During	ute "Abstinen	ice Syndromes" d	uring addiction	n to	
EXAMINER /	Jef.					•				DATE CONSIDERE	D				
*EXAMINER: I	itial if re	ference	consi	dered,	whethe	or no	ot citat	ion is i	in conformance	with MPEP 609; Draw	line through	5.2005	conformance	and not	
considered. Inch	ide copy (of this	form v	vith ne	xt com	munic	ation t	o appli	cant.						

FORM PTO-	1440			-			—						Sheet 15	of <u>24</u>
(REV. 7-80)					, ' ' ' ' '	DEPA ENT A	ATTY. DOCKE 200.1134CON	ATTY. DOCKET NO.: SERIAL N 200.1134CON 10/747,863						
		OF PI Use sev					APPLICANT(S): Benjamin OSHLACK et al.				-			
							FILING DATE: GROUP: December 29, 2003							
*EXAMINER	T													
INITIAL	 	+-	T-	ENT N	UMBE	ir T	т		DATE	NAME	CLASS	SUBCLASS	FILING	DATE
12N	OA OB	5	5	4	4	4	9	2	7/96	Aston et al.	514	608	IF APPR	OPRIAT
XA.	oc		1		9	9	├-	2	08/27/1996	Oshlack et al.	424	468		
Ari .	OD	5	5	5	2	4	2	2	09/03/1996	Gauthier et al.	514	368	 	
XIL	OE	5	5	3	6	8	3	8	9/96	Mayer et al.	514	25		
-		<u> </u>			4	0	5	2	11/96	Rose et al.	514	343		
							F(OREK	ON PATENT DO	CUMENTS				
		DOCUMENT NUMBER DAT								COUNTRY	CLASS	SUBCLASS TRANSLA		NTION
	OF	T	\exists	\neg	\neg	\neg	\neg	\dashv		·			YES	NO
	4	7				L				<u>-</u>				1
7	00				HERI	RIOR	. ART	(Inclu	ding Author, Titl	c, Date, Pertinent Pag	ges, Etc.)			
	OH	Dante :	1 81., 1	Valoxo	ne Tre	aument	of Op	iate D	ependence"; JAN	MA (1971) Vol 215, 1	Vo 13, pp. 211	78 -21 10.		
	-		· VI al.	MUN	DASAL A	Mmini	Stretion	n of N	aloxone by Para	ndeice": Umbar 3	·		T- 1	
	71							prate	Addiction": Cur	rent Psychiatric Theri	717	- (2002) VOI 0, 1		_
		Λ.		4m -						And a promise in the		n 200-012		
	01/ 1	nd The	v et al.,	"Relat	iye hir	availa	bility e	of cont	trolled release on	I morphine sulfate d	uring poly	p. 209-213.		
	- 8	and The	a (199)5) Vol	33, N	0 9, 52	4-529.	91-00 7 (t rollod-release en	e l morphine sulfate d	uring naltrexe	ne blockade"; Int	er J of Clin	Pharm
0) K J	and The	a (199)5) Vol	33, N	0 9, 52	4-529.	91-00 7 (t rollod-release en	e l morphine sulfate d	uring naltrexe	ne blockade"; Int	er J of Clin	Pharm
0) K J	and The asinski 258.	.D.R	95) Vol	33, No	o 9, 52	4-529.	Poter	maility of Morphi	el morphine sulfate d	uring naltrexo	ne blockade"; Int	tion (1977)	Pharm pp. 197-
0		and The asinski 58.	i. D.R.	OS) Vol "Asse	33, No	o 9, 52	Abuse	e Poter	maility of Morphi	netike Drugs (Metho	ds Used in M	ne blockade"; Int	tion (1977)	рр. 197-
0	DK J 2 DK	and The lasinski 258. ohnson train et 17.	.D.R	"Asse "Bupro	33, No	o 9, 52	Abuse Abuse	Poter	ntaility of interphi or Heroin Depen	al morphine sulfate d melike Druge (Metho dence", Substance U pendent humans", Gl	uring naturexo de Used in M se Disorders (in Pharm and	an)"; Drug Addict 2000) pp. 519-52 Thera (1996) Vol	60, No 2, t	pp. 197-
0	DK J 2 DK	and The lasinski 258. ohnson train et 17.	.D.R	"Asse "Bupro	33, No	o 9, 52	Abuse Abuse	Poter	ntaility of interphi or Heroin Depen	al morphine sulfate d melike Druge (Metho dence", Substance U pendent humans", Gl	uring naturexo de Used in M se Disorders (in Pharm and	an)"; Drug Addict 2000) pp. 519-52 Thera (1996) Vol	60, No 2, t	pp. 197-
0	a a a a a a a a a a	lasinski, 258. cohnson train et 17.	Et al., "C	"Asse "Bupro Opioid	33, No	o 9, 52	Abuse Abuse Abuse d Nalor	xone fi	mailty of Morphi or Heroin Depen cine in optoid-de ioid agonist-anta	nelike Drugs (Metho dence", Substance U. pendent humans", Gl gonists in humans";	uring naturexo de Used in M se Disorders (in Pharm and	an)"; Drug Addict 2000) pp. 519-52 Thera (1996) Vol	6. 60, No 2, 2	pp. 197-
0	A A A A A A A A A A	lasinski, 158. ohuson train et 17.	Et al., "C	"Asse "Bupro Dpioid	33, No	o 9, 52	Abuse Abuse Abuse d Nalor	xone fi	ntaility of Morphi or Heroin Depen cine in optoid-de ioid agonist-anta	nelike Drugs (Metho dence", Substance U pendent humans", Gl gonists in humans";	de Used in M. se Disorders (in Pharm and	an)"; Drug Addict 2000) pp. 519-520 Thera (1996) Vol	6. 60, No 2, 2	pp. 197-
0	A A A A A A A A A A	lasinski, 158. ohuson train et 17.	Et al., "C	"Asse "Bupro Dpioid	33, No	o 9, 52	Abuse Abuse Abuse d Nalor	xone fi	ntaility of Morphi or Heroin Depen cine in optoid-de ioid agonist-anta	al morphine sulfate d melike Druge (Metho dence", Substance U pendent humans", Gl	de Used in M. se Disorders (in Pharm and	an)"; Drug Addict 2000) pp. 519-520 Thera (1996) Vol	6. 60, No 2, 2	pp. 197-
	A A A A A A A A A A	lasinski, 158. ohuson train et 17.	et al., "O	"Asse "Bupro Dpinid : Abuse al., "Pl	antagor liabilit	o 9, 52 of the ine and nist off y and s cokinet Release	Abuse Abuse Abuse d Nalor	xone fi	or Heroin Dependence in optoid-dependence in optoid	nelike Drugs (Metho dence", Substance U pendent humans", Gl gonists in humans";	de Used in M. se Disorders (in Pharm and	an)"; Drug Addict 2000) pp. 519-520 Thera (1996) Vol	6. 60, No 2, 2	pp. 197-
Or O	January Januar	and The lasinski 158. chusou train et 17. ceston et 2-82. emische lidine/A	et al., "O	"Asse "Bupro Opinid Abuse al., "Pine Susi	antagor liabilit	o 9, 52 of the ine and nist off y and s cokinet Release	A-529. Abuse d Nalor feets of studies tics of le e Table	xone for opi	mailty of Morphi or Heroin Depen cine in opioid-de ioid agonist-anta idine and Naloxo Arzeim-Forsch/Dr	nelike Drugs (Metho dence", Substance Un pendent humans"; Gl gonists in humans"; I ne after Administrati ug Res. (2000) voi	de Used in M. se Disorders (in Pharm and Drug and Alco on of Tilidine io, pp. 1015-	an)"; Drug Addict 2000) pp. 519-52 Thera (1996) Vol chol Dependence (Naloxone Solution)	6. 60, No 2, 2 (1991) vol 2	pp. 197-

												T		
FORM PTO-14 (REV. 7-80)	449				U.S. D PATE			ATTY. DOCKET NO.: SERIAL NO.: 10/747,865						
·	LIST						PPLIC	APPLICANT(S): Benjamin OSHLACK et al.						
	(U	se seve	eral she	æts if n	iecessa	ry)	<u></u>	FILING DATE: GROUP: December 29, 2003 1614						
			_					CUMENTS						
*EXAMINER INITIAL		DO	CUME	IN THE	UMBE	R			DATE	NAME	CLASS	SUBCLASS	FILING DA	
AM	RA	5	6	5	6	2	9	5	08/12/1997	Oshalck et al.	424	468		
Mr.	RB	5	6	7	0		7	2	09/23/1997	Buxton et al.	424	495		
m	RC	5	6	7	2	3	6	0	09/30/1997	Sackler et al.	424	490		
Br.	RD	5	6	8	1	5	8	5	10/28/1997			1		
24										Oshlack et al.	424	494		
JY C	RE	5	7	6	3	4	5	2	06/09/1998	Miller et al.	514	282	<u> </u>	·
No.	RF	5	7	6	7	1	2	5	06/98	Crain et al.	514	282		
No.	RG	5	7	8	0	4	7	9	07/14/1998	Kim	514	282		
W.	RH	5.	7	6	7	1	2_	5	06/16/1988	Crain, et al.	514	282		
XV	RI	6	0	9	6	7	5	6	08/01/2000	Crain, et al.	514	282		
XIV.	RJ	6	1	9	4	3	8	2	02/27/01	Crain, et al.	514	.2		
SW.	RK	6	3	6	2	-	9	4	03/26/2002	Crain, et al.	514	285		
W/V	RL	6	.3	9	5	7	0	5	05/28/2002	Crain, et al.	514	2		
XI	RM	20	01	00	06	9	6	7	07/05/2001	Crain, et al.	514	253.04		
X	RN	20	Ól	00	18	4	1	3	08/30/2001	Crain, et al.	514	2		
0	1		بسننسا						ON PATENT DO				L 	
		<u></u>			~ 4DCI			JKEK		COUNTRY CLASS				
		1	JUMCI	NT NU	Mbci	(DATE		CLASS	SUBCLASS	TRANSLAT	
				,		,							YES	NO
	RO				·					·				
					THER	PRIO	R ART	[(Inch	uding Author, T	itle, Date, Pertinent Pa	ges. Etc.)			
b1	RP	Cico	nciopp				-			e Rewarding Properties		e"- Fur I Pharma		J 404
W_		pp. 1	153-159).						c nomatoring a ropo	1 Of Michigan	7 , EUI. 7 1 Harriso	2000) 10	11 404,
	_RQ	Phys	ician's	Desk	Refere	noc (2(011 se	e Revi	a. pp. 1146-114	9 and Oxycontin, op. 2	697-2701			
	RR													
	RS													
EXAMINER	7	<u>, (</u>	7,			<u> </u>	4			DATE CONSIDEREI	<u> </u>			
	7	Cot	+10	31	少.1	lse	إعلا					25,200		
AFWAN (DIPP. 1							<u> </u>		<u></u>					
considered. Inclu	nitiai it re ude copy	of this	c consi	with ne	wheth ext corr	er or no ununic	ot cital ation t	ion is o appli	in conformance icant.	with MPEP 609; Draw	/ line through	citation if not in	conformance	and not